Cantor Fitzgerald Reiterates Overweight on IRulya Therapeutics, Maintains $70 Price Target

Benzinga · 2d ago
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates IRulya Therapeutics (NASDAQ:IRLA) with a Overweight and maintains $70 price target.